Trinity Biotech

Trinity Biotech Net Debt/Equity

The Net Debt to Equity Ratio of Trinity Biotech (TRIB) as of Oct 16, 2026 is -1.85. In the previous year, Net Debt to Equity Ratio was -2.72 — a change of -32.08% (higher).

Net Debt/Equity

-1.85

YoY

-32.08%

Last updated:

Net Debt to Equity Ratio of Trinity Biotech is 2025 -1.85 . Net Debt to Equity Ratio of Trinity Biotech was 2024 -2.72 . It decreases by -32.08% higher compared to the previous year.

The Trinity Biotech Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2018
1.18 USD
Jan 1, 2019
18.20 USD
Jan 1, 2020
-34.71 USD
Jan 1, 2021
-229.61 USD
Jan 1, 2022
-30.16 USD
Jan 1, 2023
-2.66 USD
Jan 1, 2024
-2.72 USD
Jan 1, 2025
-1.85 USD
The Trinity Biotech Net Debt/Equity history
YEARNet Debt/EquityYoY
-1.85-32.08%
-2.72+2.10%
-2.66-91.18%
-30.16-86.87%
-229.61+561.59%
-34.71-290.71%
18.20+1,448.35%
1.18+103.95%
0.58+218.78%
0.18-1,089.19%
-0.02-172.07%
0.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech PLC is a healthcare company based in Bray, Ireland, with a focus on developing, manufacturing, and marketing medical diagnostic products. The company serves the clinical laboratory and point-of-care segments of the diagnostic market. Trinity Biotech employs 579 full-time staff and has been publicly traded since its IPO on October 21, 1992. Its products are designed to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company operates through two geographic segments: the Americas and Rest of World. Product categories include point-of-care diagnostics, emergency medicine diagnostics, clinical laboratory reagents, and blood bank screening. The company's point-of-care brands are Uni-Gold and Recombigen, while its emergency medicine diagnostics cover acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. Trinity Biotech supplies the clinical laboratory market with reagent products and other solutions through its clinical chemistry business. The blood bank screening division manufactures products to screen donated blood for transfusion-transmissible infections. The company's website is www.trinitybiotech.com. Trinity Biotech PLC is listed on the stock market under the ticker TRIB and ISIN US8964385046. The company's headquarters are located in Bray, Wicklow, Ireland. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Net Debt to Equity Ratio of Trinity Biotech is -1.85 in 2025.

Net Debt to Equity Ratio of Trinity Biotech changed from -2.72 to -1.85, representing a -32.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Trinity Biotech

All Key Metrics — Trinity Biotech